

MEDCOM USA INC  
Form 10QSB  
February 14, 2008

---

---

U.S. Securities and Exchange Commission  
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

T

Quarterly Report Pursuant to Section 13 or  
15(d) of

the Securities Exchange Act of 1934

For the quarterly period ended December 31, 2007.

£ Transition Report Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act

For the transition period from N/A to N/A

Commission File No. 0-25474

MedCom USA, Incorporated  
(Name of small business issuer as specified in its charter)

Delaware  
State of Incorporation

65-0287558  
IRS Employer Identification No.

7975 North Hayden Road, Suite D-333  
Scottsdale, AZ 85258  
(Address of principal executive offices)  
(480) 675-8865  
(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  T    No  £

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  £    No  T

Edgar Filing: MEDCOM USA INC - Form 10QSB

The number of shares of the issuer's common equity outstanding as of February 12, 2008 was 94,930,217 shares of common stock.

Transitional Small Business Disclosure Format (check one):

Yes  No

---

---

1

---

MEDCOM USA INCORPORATED  
 INDEX TO FORM 10-QSB FILING  
 FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2007

TABLE OF CONTENTS

PART I		PAGE
FINANCIAL INFORMATION		
Item 1.	Financial Statements	
	<u>Condensed Consolidated Balance Sheet As of December 31, 2007</u>	3
	<u>Condensed Consolidated Statements of Operations For the Three and Six months ended December 31, 2007 and 2006</u>	4
	<u>Condensed Consolidated Statements of Cash Flows For the Six months ended December 31, 2007 and 2006</u>	5
	<u>Notes to Condensed Financial Statements</u>	6 - 9
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	9 - 18
Item 3.	<u>Control and Procedures</u>	18-19
PART II		
OTHER INFORMATION		
Item 1.	<u>Legal Proceedings</u>	19
Item 2.	<u>Changes in Securities and Small Business Issuer Purchases of Equity Securities</u>	19
Item 3.	<u>Defaults upon Senior Securities</u>	20
Item 4.	<u>Submission of Matters to a Vote of Security Holders</u>	20
Item 5.	<u>Other Information</u>	20
Item 5.	<u>Exhibits</u>	20
<b>CERTIFICATIONS</b>		
Exhibit 31 – Management certification		
Exhibit 32 – Sarbanes-Oxley Act		

Table of Contents

## PART I – FINANCIAL INFORMATION

## ITEM 1 – FINANCIAL STATEMENTS

MEDCOM USA, INC.  
CONDENSED CONSOLIDATED BALANCES SHEETS  
AS OF DECEMBER 31, 2007

## ASSETS:

	December 31, 2007 (unaudited)
<b>CURRENT ASSETS</b>	
Cash	\$ -
Licensing contracts - current portion, net	602,451
Prepaid expenses and other current assets	108,846
Total current assets	711,297
<b>PROPERTY AND EQUIPMENT, net</b>	
	462,517
Licensing contracts - long-term portion, net	211,203
Note receivable affiliates	257,755
Other assets	21,507
<b>TOTAL ASSETS</b>	<b>\$ 1,664,279</b>

## LIABILITIES AND STOCKHOLDERS' DEFICIENCY:

## CURRENT LIABILITIES:

Accounts payable	\$ 182,899
Bank overdraft	14,911
Accrued expenses and other liabilities	43,663
Dividend payable	23,750
Notes from affiliates	791,000
Deferred revenue - current portion	575,818
Licensing obligations - current portion	1,889,279
Total current liabilities	3,521,320
Licensing obligations - long-term portion	3,156,789
Deferred revenue	382,490
<b>TOTAL LIABILITIES</b>	<b>7,060,599</b>

## STOCKHOLDERS' DEFICIENCY:

Convertible preferred stock, series A \$.001 par value, 52,900 shares designated, 4,250 issued and outstanding	4
Convertible preferred stock, series D \$.01 par value, 50,000 shares designated, 2,850 issued and outstanding	29
Common stock, \$.0001 par value, 175,000,000 shares authorized, 94,930,217 issued and outstanding as of December 31, 2007	9,494
Paid-in capital	85,090,153

Treasury stock	(37,397)
Accumulated deficit	(90,458,603)
Total stockholders' deficiency	(5,396,320)
<hr/>	
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	\$ 1,664,279

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

MEDCOM USA, INC.

## CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2007 AND 2006

	Three Months Ended		Six Months Ended	
	2007	2006	2007	2006
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
<b>REVENUES</b>				
Terminal sales	-	\$ 4,058	\$ -	\$ 30,481
Service	508,044	899,498	1,171,615	1,820,242
Licensing fees	203,174	564,348	476,659	1,217,772
	711,218	1,467,904	1,648,274	3,068,495
<b>COST OF DELIVERABLES</b>	260,080	377,436	591,685	932,007
<b>GROSS PROFIT</b>	451,138	1,090,468	1,056,589	2,136,488
<b>OPERATING EXPENSES</b>				
General and administrative expenses	517,576	967,235	1,138,507	1,941,813
Sales and marketing expenses	16,667	52,596	33,467	82,749
Depreciation and amortization	-	321,293	-	763,450
Total operating expenses	534,243	1,341,124	1,171,974	2,788,012
<b>OPERATING LOSS</b>	(83,105)	(250,656)	(115,385)	(651,524)
<b>OTHER (INCOME) AND EXPENSES</b>				
Interest expense	36,631	291,488	236,050	389,589
Interest income	(50,341)	(102,324)	(119,188)	(205,927)
Impairment of assets	-	-	-	27,040
Legal settlement	-	9,000	-	48,600
Other income	-	(42,585)	-	(42,585)
Total other (income) expense	(13,710)	155,579	116,862	216,717
<b>NET LOSS</b>	(69,395)	\$ (406,235)	\$ (232,247)	\$ (868,241)
<b>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</b>				
Basic and diluted:	94,847,174	84,448,739	94,359,266	79,368,685
<b>NET LOSS PER SHARE:</b>				
Basic and diluted:	(0)	\$ (0.00)	\$ (0.00)	\$ (0.01)

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

MEDCOM USA, INC.  
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
 FOR THE SIX MONTHS ENDED DECEMBER 31, 2007 AND 2006

	2007 (unaudited)	2006 (unaudited)
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net loss	\$ (232,247)	\$ (868,241)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	110,592	763,450
Issuance of stock as consideration for services	-	720,720
Issuance of stock in lieu of rent expense	8,500	-
Impairment of assets	-	27,040
Changes in operating assets and liabilities:		
Prepaid and other current assets	88,294	46,120
Accounts payable	59,744	-
Accrued expenses and other liabilities	(10,779)	(662,553)
Deposits	(3,850)	
Deferred revenue	(1,093,050)	(1,358,728)
Net cash used in operating activities	(1,072,796)	(1,332,192)
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchase of equipment	(28,123)	(158,025)
Licensing contracts - current portion	187,799	(433,117)
Licensing contracts - long-term portion	336,020	-
Notes from affiliates	(195,115)	(182,157)
Net cash provided by (used in) investing activities	300,581	(773,299)
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Bank overdraft	14,911	-
Advances from related party	486,000	-
Principal repayments on capital leases	-	(831,944)
Net repayments of (advances) to Affiliate	-	(826,198)
Licensing obligation - current portion	(446,545)	375,475
Licensing obligation - long-term portion	(200,387)	-
Cost of raising capital	(65,975)	
Proceeds from sale of common stock	958,001	3,452,324
Net cash provided by financing activities	746,005	2,169,657
<b>(DECREASE) INCREASE IN CASH</b>	<b>(26,210)</b>	<b>64,166</b>
<b>CASH, BEGINNING OF YEAR</b>	<b>26,210</b>	<b>1,148</b>
<b>CASH, END OF YEAR</b>	<b>\$ -</b>	<b>\$ 65,314</b>
<b>SUPPLEMENTAL CASH FLOW INFORMATION:</b>		
Interest paid	\$ 236,000	\$ 298,000
Issuance of stock for acquisition of assets	\$ 61,000	\$ -

The accompanying notes are an integral part of these condensed consolidated financial statements



Table of Contents

MEDCOM USA INCORPORATED

NOTES TO CONDENSED FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED DECEMBER 31, 2007 and 2006

1. BASIS OF PRESENTATION

MedCom USA, Inc. (the "Company") a Delaware corporation was formed in August 1991 under the name Sims Communications, Inc. The Company's primary business was providing telecommunications services. In 1996 the Company introduced four programs to broaden the Company's product and service mix: (a) cellular telephone activation, (b) sale of prepaid calling cards, (c) sale of long distance telephone service and (d) rental of cellular telephones using an overnight courier service. With the exception of the sale of prepaid calling cards and cellular telephone activation, the other programs were discontinued in December 1997. The Company changed its name to MedCom USA, Inc. in October 1999. During the fiscal years of 1999 and continuing through present, the Company directed its efforts in medical information processing.

2. GOING CONCERN

The accompanying condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America which contemplate continuation of the Company as a going concern. However, the Company has year end losses from operations and had minimal revenues from operations the six months ended December 31, 2007. During six months ended December 31, 2007 the Company incurred a net loss of \$232,247 and has an accumulated deficit of \$90,458,603. Further, the Company has inadequate working capital to maintain or develop its operations, and is dependent upon funds from private investors and the support of certain stockholders.

These factors raise substantial doubt about the ability of the Company to continue as a going concern. The condensed financial statements do not include any adjustments that might result from the outcome of these uncertainties. In this regard, Management is proposing to raise any necessary additional funds through loans and additional sales of its common stock. There is no assurance that the Company will be successful in raising additional capital.

3. INTERIM FINANCIAL STATEMENTS

The accompanying interim unaudited condensed financial information has been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although management believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position of the Company as of December 31, 2007 and the related operating results and cash flows for the interim period presented have been made. The results of operations of such interim periods are not necessarily indicative of the results of the full fiscal year. For further information, refer to the financial statements and footnotes thereto included in the Company's 10-KSB and Annual Report for the fiscal year ended June 30, 2007.

Table of Contents

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Summarized below are the significant accounting policies of MedCom USA, Inc. (“we,” “MedCom,” or the “Company”). Unless otherwise indicated, amounts provided in these notes to the financial statements pertain to continuing operations.

Revenue Recognition

Statement of Position Software Revenue Recognition (“SOP”) 97-2 applies to all entities that license, sell, lease, or market computer software. It also applies to “hosting” arrangements in which the customer has the option to take possession of the software. Hosting arrangements occur when end users do not take possession of the software but rather the software resides on the vendor’s or a third party’s hardware, and the customer accesses and uses the software on an as-needed basis over the Internet or some other connection. It does not, however, apply to revenue earned on products containing software incidental to the product as a whole or to hosting arrangements that do not give the customer the option of taking possession of the software.

SOP 97-2 allows for revenue to be recognized in accordance with contract accounting when the arrangement requires significant production, modification, or customization of the software. When the arrangement does not entail such requirements, revenue should be recognized when persuasive evidence of an agreement exists, delivery has occurred, the vendor’s price is fixed or determinable, and collectibility is probable.

The largest part of revenues stems from vendors’ license fees associated with software. The Company recognizes revenue from license fees when the software is shipped to the customer. The amount and timing of revenue recognition is based on the multiple-element arrangements that provide for multiple software deliverables [e.g., software products, upgrades or enhancements, post contract customer support (PCS), or other services]. In hosting arrangements that are within the scope of SOP 97-2, multiple elements might include specified or unspecified upgrade rights, in addition to the software product and the hosting service. The software provider often charges a single fee that must be allocated to the products delivered.

In an arrangement with multiple deliverables, Emerging Issues Task Force Revenue Arrangement with Multiple Deliverables (“EITF”) 00-21 requires that the delivered items be considered a separate unit of accounting if the delivered items have value to the customer on a stand-alone basis, if there is objective and reliable evidence of the fair value of the undelivered items, and if the arrangement includes a general right of return for the delivered item, or if delivery or performance of the undelivered items is considered probable and substantially in the control of the vendor. EITF 00-21 requires allocation of the vendor’s fee to the various elements based on relative fair value of each element’s stand-alone value.

In general, both SOP 97-2 and EITF 00-21 require allocating revenue to all of the elements of a multiple-deliverable arrangement using the relative fair value method, where objective and reliable evidence of fair value is present for all the products contained in the group.

Management has established vendor-specific objective evidence (“VSOE”) for access fee, equipment, provider enrollment fees, EDI connectivity fees, payer/provider fees, benefit verification fees, referral transfer fees, service authorization fees, claim status, training, support, program upgrades, carrier editions, and customized reports. Revenue is accordingly allocated and recognized based on the value of deliverables.

The Company has substantial expenses such as commission, royalties, software portal, and the software deliverables and pays those costs at the execution of the contract. The Company accumulates the entire contract of licensing and gateway access fees and records it as the licenses and gateway access fees receivables. The Company recognizes

revenue in accordance with SOP 97-2 when the software is delivered to the professional and recognizes the remaining portion of the contract over the life of the contract. The Company recognizes the revenue of the contract at the time of the deliverables and execution of the contract since the Company has substantial costs for each element of the multiple deliverables included in the contract. The remaining portion is recognized monthly in accordance the agreement. The Company further accrues the prepaid licensing expense, accrued deliverables under the fixed and determinable licensing arrangement. The Company only recognizes revenue upon completion of each deliverable is does not recognized revenue upfront which is not fixed or determinable.

7

---

Table of Contents

The Company has adopted the Securities and Exchange Commission's Staff Accounting Bulletin (SAB) No. 104, Revenue Recognition, which provides guidance on the recognition, presentation and disclosure of revenue in financial statements.

## 5. EQUITY

During six months ended December 31, 2007 and 2006:

Quarter Ended	Stock issued for Cash	Cash Received	Stock issued for Services
September 30, 2006	7,384,373	\$ 2,178,991	1,837,331
December 31, 006	2,579,331	\$ 1,273,333	4,726,870
<b>Total Issued</b>	<b>9,963,704</b>	<b>\$ 3,452,324</b>	<b>6,564,201</b>
September 30, 2007	1,847,357	\$ 803,001	-
December 31, 2007	310,000	\$ 155,000	-
<b>Total Issued</b>	<b>2,157,357</b>	<b>\$ 958,001</b>	<b>-</b>

During the six months ended December 31, 2006, the Company issued 9,963,704 shares of its common stock for \$3,452,324. The shares were issued to third parties in a private placement of the Company's common stock. The shares were sold throughout the quarter ended December 31, 2006, ranging from \$.75 per share at the beginning of the period to \$.25 per share at the end of the period.

The Company has issued shares of its common stock as consideration to consultants for the fair value of the services rendered. The value of those shares is determined based on the trading value of the stock at the dates on which the agreements were entered into for the services and the value of services rendered. During the period ended December 31, 2006, the Company granted to consultants, 6,564,201 shares of common stock valued between \$.75 - \$.25. The values of these common shares issued were expensed during the year.

In December 31, 2007 the Company issued of 2,157,357 shares of its common stock for \$958,001. The shares were issued to third parties in a private placement of the Company's common stock. The shares were sold throughout the quarter ended December 31, 2007, ranging from \$.35 per share at the beginning of the period to \$.48 per share at the end of the period. Commissions of approximately \$65,975 are recorded as a charge in additional paid in capital as direct costs associated with the raising of equity capital.

## 6. RELATED PARTY TRANSACTIONS

The Company's president and chairman is an 8% shareholder and its sole officer and director of the Company. The chairman controls American Nortel Communications, Inc. which is a 22% shareholder in the Company. The chairman also controls Card Activation Technologies, Inc. ("Card") in which MedCom owns 37% of Card. During the year ended June 30, 2002, the Company moved its administrative offices into space occupied by this related entity. The Company shares office space and management and administrative personnel with this related entity. Certain of the Company's personnel perform functions for the related entity but there was no allocation of personnel related expenses to the related entity in the six months ended December 31, 2007 and 2006.



Table of Contents

The Company frequently receives advances, and advances funds to an entity controlled by the Company's president and which is a significant shareholder of the Company to cover short-term cash flow deficiencies. In the six months ended December 31, 2007 the chairman advanced \$486,000. The balance due to this affiliate for the six months ended December 31, 2007 and 2006 was \$791,000 and \$212,914, respectively. The advances are generally short term in nature with an interest rate of 9%. The advances of \$791,000 still remain outstanding as of December, 2007.

Card's operating requirements has been and will be funded primarily from its related party entity MedCom USA, Inc. Card will use funds advanced by MedCom. Currently, the Card costs are limited to professional fees and subject to a contingency fee from our patent litigation attorneys. MedCom will continue to provide funds through a revolving line of credit of \$250,000 which funds will be drawn down on an as needed basis until Card begin to realize sufficient revenues from royalty payments. Once Card begins receiving royalties, we expect the revenues of such royalties shall permit us to be self-funding.

Card has financed operations by advances from, MedCom USA Incorporated which total \$257,755 through December 31, 2007.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management's Discussion and Analysis contains various "forward looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding future events or the future financial performance of the Company that involve risks and uncertainties. Certain statements included in this Form 10-QSB, including, without limitation, statements related to anticipated cash flow sources and uses, and words including but not limited to "anticipates", "believes", "plans", "expects", "future" and similar statements or expressions, identify forward looking statements. Any forward-looking statements herein are subject to certain risks and uncertainties in the Company's business, including but not limited to, reliance on key customers and competition in its markets, market demand, product performance, technological developments, maintenance of relationships with key suppliers, difficulties of hiring or retaining key personnel and any changes in current accounting rules, all of which may be beyond the control of the Company. The Company adopted at management's discretion, the most conservative recognition of revenue based on the most astringent guidelines of the SEC in terms of recognition of software licenses and recurring revenue. Management will elect additional changes to revenue recognition to comply with the most conservative SEC recognition on a forward going accrual basis as the model is replicated with other similar markets (i.e. SBDC). The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth therein.

Forward-looking statements involve risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors and risks that could affect our results and achievements and cause them to materially differ from those contained in the forward-looking statements include those identified in the section titled "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended June 30, 2007, as well as other factors that we are currently unable to identify or quantify, but that may exist in the future.

## Table of Contents

In addition, the foregoing factors may affect generally our business, results of operations and financial position. Forward-looking statements speak only as of the date the statement was made. We do not undertake and specifically decline any obligation to update any forward-looking statements.

### Overview

MedCom USA, Inc. (the "Company"), a Delaware corporation, was formed in August 1991 under the name Sims Communications, Inc. The Company's primary business was providing telecommunications services. In 1996 the Company introduced four programs to broaden the Company's product and service mix: (a) cellular telephone activation, (b) sale of prepaid calling cards, (c) sale of long distance telephone service and (d) rental of cellular telephones using an overnight courier service. With the exception of the sale of prepaid calling cards and cellular telephone activation, the other programs were discontinued in December 1997. The Company changed its name to MedCom USA, Inc. in October 1999. During the fiscal years of 1999 and continuing through present, the Company directed its efforts in medical information processing.

### Healthcare Transaction Processing Business

#### MedCom System

The Company provides innovative technology-based solutions for the healthcare industries that enable users to efficiently collect, use, analyze and disseminate data from payers, health care providers and patients. The MedCom System currently operates through a point-of-sale terminal or web portal. The point-of-sale terminals are purchased from Hypercom Corporation (Hypercom). The Company business plan consists of offering a service bundled package that would have the capability of processing unlimited claims and eligibility verification for monthly service fees.

The Company's "web portal" encourages customers to process their medical claims through an online portal. Many customers purchase the terminal for the front office and the portal system for the back office to take advantage of the ease of both products.

#### Financial Transaction Services

The Company's credit card center and check services provides a combination of services designed to improve collection and approvals of credit/debit card payments along with the added benefit and convenience of personal check guarantee from financial institutions.

Easy-Pay is an accounts receivable management program that allows a provider to swipe a patient's credit card and store the patient's signature in the terminals, and bill the patient's card at a later date when it is determined what services rendered were not covered by the patient's insurance. Also, Easy-Pay allows patient's the added benefit and convenience of a one-time payment option or a recurring installment payments that will be processed on a specified date determined by the provider and patient. These options insure providers that payments are timely processed with the features of electronic accounts receivable management. These services are all deployed thorough point-of-sale terminals or web portal. Using the MedCom system, medical providers are relieved of many of the problems associated with billings and account management, and results in lower administrative documentation and costs.

## Table of Contents

### Patient Eligibility

The MedCom System is also an electronic processing system that consolidates insurance eligibility verification, processes medical claims, and monitors referrals. The MedCom System allows a patient's primary care physician to request approval from the patient's insurance carrier or managed care plan for a referral to a secondary physician or specialist. The secondary physician or specialist can use the MedCom system to verify referrals are approved by the patient's insurance carrier. The MedCom system's referral capabilities reduce documentation and administrative costs which results in increased productivity and greater patient information for the specialist, as well as a written record of the referral authorization.

The MedCom System can record and track encounters between patients and health care providers for performance evaluation and maintenance of records. After examining a patient the physician enters a patient's name, procedure code and diagnostic code at a nearby terminal. This information is then uploaded to MedCom's computer network, processed and transmitted back to the provider formatted in both summary and/or detailed reports, and as a result healthcare providers' reimbursements are accelerated and account receivables are reduced. In managements' opinion, the average time it takes the healthcare providers to collect payments from insurance carriers and plans decreases from an average of 89 days to 7-21 days. Health care providers will benefit from a 100% paperless claim processing system.

Presently, the MedCom system was able to retrieve on-line eligibility and authorization information from approximately 450 medical insurance companies and plans. Included in this group is the newly activated Medicare Part A & B eligibility for all 50 states. This gives us access to over 42 million lives. The system also electronically processes and submits claims for its healthcare providers to over 1,700 companies. These insurance providers include CIGNA, Prudential, Oxford Health Plan, United Health Plans, Blue Cross, Medicaid, Aetna, Blue Cross/Blue Shield, and Prudential.

### Competition

Competing health insurance claims processing and/or benefit verification systems include WebMD (HLTH), NDC Health (NDC), and Per-se Technologies (PSTI). There are similar companies that compete with the Company with respect to its financial transaction processing services performed by the MedCom system. These companies compete with the Company directly or to some degree. Many of these competitors are better capitalized than the Company, and maintain a significant market share in their respective industries.

The Company offers multiple training options for its products and services and is easily accessed at [www.MedComUSA.com](http://www.MedComUSA.com). Onsite training and teleconferencing, and technical support assistance are also features offered to health care providers. Also, a 24-hour terminal replacement program and system upgrades are offered.

### Marketing Strategy

MedCom has broadened marketing strategy to reduce cost and increase efficiency. The Company has employed telesales strategy to decrease dependency on individual sales personnel. The Company just completed its final phase of its portal software development which has broadened the sales model to both a terminal and portal sale. The Company has entered into telesales agreements which have implemented the new marketing strategy. The completion of the portal will increase sales to hospitals which results in multiple sales. In addition, the portal has become popular for individual doctors, dentist, and other healthcare professionals which often results in a single or possibly multiple sales. The Company has focused its sales to hospitals as a growing revenue source.



In the past the Company built its marketing around a strategy of expanding its sales capacity by using experienced external Independent Sales Organizations (ISO) and putting less reliance on an internal sales force. MedCom has set-up these Independent Sales Organizations (ISOs) to market and distribute the MedCom System throughout the U.S. Financial service companies comprise an important sales channel that views the healthcare industry as an important growth opportunity. Also 6% of all healthcare payments are made with a credit card today. However, according to a recent survey 55% of all consumers would prefer to pay doctor and hospital visits by credit/debit card.

## Table of Contents

MedCom has been expanding its position with hospitals and working closely with hospital consultants and targeted seminars. The Company, with its new Online web portal product and Medicare access, is becoming an increasingly valuable tool for the outpatient and faculty practice areas of hospitals. While the ISO groups focus on individual doctors, dentists and clinics, our hospital team is focusing on multiple unit sales opportunities with hospitals around the country.

### Service Agreements

During June 2005, the Company entered into a service agreement with TESIA-PCI, Inc. This agreement was to replace and service and support, at a minimum 1,500 POS terminals inclusive of eligibly, claims processing, credit card processing for TESIA's dental providers.

### Patent

Card Activation Technologies Inc. ("Card") is a Delaware corporation headquartered in Chicago, Illinois that owns proprietary patented payment transaction technology used for electronic activation of phone, gift and affinity cards. MedCom owns 60,000,000 shares of common stock of Card which represents 41% of the issued and outstanding shares of Card.

The patent was transferred to Card by MedCom on the formation of Card and in exchange for 146,770,504 shares of Common Stock.

Card was incorporated in August 2006 in order to own and license, the assigned patent which covers payment transaction technology and the process for taking a card with a magnetic strip or other data capture mechanism and processing transactions or activating the card. This process is utilized for prepaid phone cards, gift cards, and debit-styled cards. As of the date of this report, Card has entered into a license agreement with McDonald's Corporation. Card has one principal asset, the patented payment transaction technology assigned from MedCom, and one full time and one part-time employee. Card does not expect to commence full scale operations or generate additional revenues until late 2007. Since incorporation, Card has not made any significant purchases or sale of assets, nor has Card been involved in any mergers, acquisitions or consolidations. Card has filed four lawsuits to enforce its patented technology and has sent license agreement requests to a number of companies in order to obtain license agreements with entities that Card believes are infringing its patent.

Card has the ability to market and sell licensing opportunities for the patented technology of processing debit-styled transactions, including processing transactions with debit, phone and gift cards and also activating and adding value to those debit-styled cards. New View Technologies, which was acquired by MedCom USA, developed the patent and all patents were ultimately assigned to Card.

### Revenues

A sales staff meets with a dental or medical professional. During that initial meeting a demo is displayed so the professional has first hand knowledge of the software and its use. At the time of the meeting a noncancellable licensing agreement is executed along with a service agreement. The license agreement indicates the life of the agreement if the customer wants check readers, pin pads, portal wedge, etc. with the software. These units allow the professional to swipe a credit card and medical card for the software to read.

Table of Contents

The professional executes the licensing agreement which states the terms for a period of 24 – 60 month agreements, number of portal/units needed, at which location the portals will be used, the monthly licensing amount, (which varies per contract) type of contract whether dental or medical, the amount of the gateway access fee (usually \$24.95 per month which includes provider enrollment), EDI connectivity, a the monthly maintenance charges that are billed when used as commercial benefit verification, Referral transactions, claims status, service authorizations, maintenance, training, support, programs upgrades, carrier additions, and customized reports. The professional then provides MedCom a voided check or credit card number to automatically withdraw or charge the licensing fee and gateway access fees on a monthly basis. Also those automatic withdrawals include the maintenance charges based upon usage. The professional also agrees to allow MedCom to provide merchant services for Visa/MasterCard. MedCom further agrees that the monthly fees charged for gateway access and licensing fees will commence with in 10 day so of the execution of the noncancellable agreements.

MedCom has substantial expenses for each element is delivers such as commission, royalties, software portal, and the software deliverables and pays those costs at the execution of the contract. The Company accumulates the entire contract of licensing and gateway access fees and record as the licenses and gateway access fees receivables. The Company recognizes revenue in accordance with SOP 97-2 when the software is delivered to the professional and recognizes the remaining portion of the contract over the life of the contract. The Company recognizes the revenue of the contract at the time of the deliverables and execution of the contract since the Company has substantial costs to be recognized at the time of the multiple deliverables of each element. The remaining portion is recognized monthly in accordance with the agreement. The Company further accrues the prepaid licensing expense, accrued deliverables under the fixed and determinable licensing arrangement.

The Company continues to recognize transaction fees as they receive them. The Company collects other fees based upon usage of the software and are not fixed fees such as gateway access and licensing fees and are part of the deliverables such as Provider enrollment, EDI Connectivity, Payer/Provider, Benefit Verification – Govt Billings, Referral Transfers – Govt billing, Benefit Verification – Commercial, Referral Transfer – Commercial, Claim Status, Service Authorization, Maintenance, Training, Support, Program Upgrades, Carrier Editions, and Customized Reports. The Company calls these fees transaction fees, they are not a fixed and determinable, therefore are not accrued but are recognized when used by the customer.

The Company enters into a long term debt and long term receivable for the life of the license agreement which is non cancelable agreement. The Company collects the monthly licensing and gateway access fees every 30 days over the life of the contract. The Company does not collect the entire contract within 30 days but over the terms of the agreement therefore records deferred revenue for the portion of the contract that is recognized over the contract.

The Company finances the licensing fees agreement while the gateway access fees are received over the life of the contract. The license fees are financed through Ladco in prior periods and in fiscal 2006 and 2007 through LeeCo. The Company has a standard financing the agreement through LeeCo through the term of the contract.

Revenues from the MedCom system are generated through the sale of the portal software, software terminals, and processing insurance benefit eligibility/verification, insurance claims, and financial transaction processing. The Company receives a fixed amount per software portal and software terminal, and also receives fees for each transaction processed through the MedCom System. Revenue sources include fees for financial transactions processed through the software portal and software terminal, fees for collection of receivables if the Company provides billing services, fees associated with reimbursements made by insurance carriers for submitting claims that are processed electronically, fees for using the system's referral program and, fees for processing uploaded data. The Company also markets a complete billing service using the MedCom System for hospitals and large practice groups. The Company receives a percentage of the billing amount collected under these arrangements.



## Table of Contents

The Company has adopted the Securities and Exchange Commission's Staff Accounting Bulletin (SAB) No. 104, which provides guidance on the recognition, presentation and disclosure of revenue in financial statements.

### Additional Information

MedCom files reports and other materials with the Securities and Exchange Commission. These documents may be inspected and copied at the Commission's Public Reference Room at 100 F Street, NE, Washington, DC 20549. You can obtain information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330. You can also get copies of documents that the Company files with the Commission through the Commission's Internet site at [www.sec.gov](http://www.sec.gov).

### Results of Operations

Revenues for the three months ended December 31, 2007 decreased to \$711,218 from \$1,467,904 for the three months ended December 31, 2007 2006. Revenues for the six months ended December 31, 2007 decreased to 1,648,274 from \$3,068,495 for the six months ended December 31, 2006. This was a 48% reduction in revenues three months ended December 31, 2007 and a 54% for the six months ended December 31, 2007. This decrease in revenue is directly the result of changes in the Company's strategic direction in core operations. The Company continues to aggressively pursue and devote its resources and focus its direction in electronic medical transaction processing. The Company's agreement with its credit facility in connection with the licensing of terminals and portal transactions therewith, the Company must defer revenue on licensing agreement of the terminals and portal software. The decline in revenues is directly related in 2006 the Company executed large licensing agreements with large hospital groups such as Mount Sinai, St. Vincent, Beth Israel, and Continuum Partners. The large hospital groups that licensed our portals licensed at a minimum of 35 portal systems per group. In the case of St. Vincent our portal system is used exclusively by all of their hospital facilities. However, in December 31, 2007 the Company was licensing to more individual doctor and dental groups that were directly related to our decrease in revenues.

The Company further refocused its sales to large practice management groups to sell multiple web portals and further has expanded its exposure and future sales with a large dental group. The Company is negotiating and developing relationships with the practice management and dental groups and the Company will not realize those efforts until fourth quarter fiscal year 2008.

Cost of deliverables for three months ended December 31, 2007 increased to \$260,080 from \$377,436 for three months ended December 31, 2006. Cost of deliverables for six months ended December 31, 2007 decreased to \$591,685 from \$932,007 for the six months ended December 31, 2006. This was a 69% reduction in cost of deliverables three months ended December 31, 2007 and a 63 % for the six months ended December 31, 2007. The Company has developed the MedComConnect portal package that will decrease the cost of each element of the multiple deliverables as the Company focuses on the sale of the portal software which rendered the medical terminals sales no longer the core revenue model for the Company. The decrease in cost of deliverables is directly related to the decrease in revenues from the two quarter ended December 31, 2007. Also the decrease is related to the decrease then elimination of 25% royalty payments to third parties. Further the Company no longer pays commission on future revenues from its noncancellable licensing agreements. Commissions are paid at inception of the licensing agreement at a 10% rate and there are no future payments on residuals revenues from gateway access fees and licensing fees. The Company paid the future royalty obligation and commitment and is no longer obligated to pay royalties now and in the future. In the prior period comparative there was a spike in costs with TESIA, a larger vendor contract.

Table of Contents

Selling expenses for three months ended December 31, 2007 decrease to \$16,667 from \$52,596 for three months ended December 31, 2006. Selling expenses for six months ended December 31, 2007 decreased to \$33,467 from \$82,749 for the six months ended December 31, 2006. This was a 32% reduction in selling expenses three months ended December 31, 2007 and a 40% for the six months ended December 31, 2007. . This decrease is primarily the result of marketing efforts and includes commissions paid to internal sales personnel to market the Company's products and services. The Company has introduced the telesales marketing strategy for less expensive sales force and more effective in the future.

General and administrative expenses for the three months ended December 31, 2007 decreased to \$517,576 from \$967,235 for three months ended December 31, 2006. General and administrative expenses for six months ended December 31, 2007 decreased to \$1,138,507 from \$1,941,813 the six months ended December 31, 2006. This was a 54% reduction in general and administrative expenses three months ended December 31, 2007 and a 58% for the six months ended December 31, 2007. This decrease is attributed to the Company's reduction of workforce in their New York operations as the Company has streamlined overall employee use. That is the Company has implemented and advanced its in-house software to perform many of the services the prior employees were performing manually.

Interest expense for three months ended December 31, 2007 decrease to \$36,631 from \$291,488 for the three months ended December 31, 2006. Interest expenses for six months ended December 31, 2007 decrease to \$236,050 from \$389,589 for the six months ended December 31, 2006. This was a 49% reduction in interest expense three months ended December 31, 2007 and 61% for the six months ended December 31, 2007. This decrease is a result of renegotiation of the Company's credit facility with Ladco. Also, expenses were incurred and paid on notes the Company has outstanding with LeeCo. Further the Company's renegotiation has reduced the accrual of interest below 3% until paid in full in 2009. We have also have been paying down the LeeCo obligation which has grown from the increase in financing through LeeCo Financial Inc. The payments to Ladco represented a high interest rate and the Company has systematically reduced the Ladco debt. Interest income for the three months ended December 31, 2007 decreased to \$50,341 from \$102,324 for the three months ended December 31, 2006. Interest income for the six months ended December 31, 2007 decreased to \$119,188 from \$205,927 for the six months ended December 31, 2006. This was a 49% reduction in interest income three months ended December 31, 2007 and 58% for the six months ended December 31, 2007. The decrease is due to the reduction in current sales of the portal software from our license agreements. The licensing agreements are noncancellable licensing of our portal software in which we charge interest expense and interest income related to the life of the licensing agreement.

The loss for three months ended December 31, 2007 decreased to (\$69,395) from (\$406,235) for the three months ended December 31, 2006. The loss for the six months ended December 31, 2007 decreased to (\$232,247) from (\$868,241) for the six months ended December 31, 2006. This was a 17% reduction in loss three months ended December 31, 2007 and 27% for the six months ended December 31, 2007. The decrease is due to the reduction in revenue, sales force, royalty expense, commissions, and reduction in operations in our New York facility.

No tax benefit was recorded on the expected operating loss for December 31, 2007 and 2006 as required by Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes. For the quarter ended we do not expect to realize a deferred tax asset and it is uncertain, therefore we have provided a 100% valuation of the tax benefit and assets until we are certain to experience net profits in the future to fully realize the tax benefit and tax assets.

Table of Contents

## LIQUIDITY AND CAPITAL RESOURCES

The Company's operating requirements have been funded primarily on its sale of licensing agreements with hospitals, medical, and dental professionals and sales of the Company's common stock. During the six months ended December 31, 2007, the Company's net proceeds from the licensing of the Company's software portals were \$251,267 as compared to 2006 of \$375,473. The Company received \$958,001 as compared to 2006 of \$3,452,324 in proceeds from the sale of common stock. The Company believes that the cash flows from its monthly service and transaction fees are inadequate to repay the capital obligations and has relied upon the sale of common stock through a private place to sustain its operations.

Cash (used) operating activities for the six months ended December 31, 2007 was (\$1,072,796) compared to (\$1,332,192) for 2006. The Company's focus on core operations results in an increase in licenses receivable. The Company receives payments from customers automatically through electronic fund transfers. Collection cycles of the monthly noncancellable licenses are generally paid monthly. The Company has grown its operations to begin to reduce the deficit cash flow positions. However the Company is still operating in a deficit. The Company reduced its expenses by exercising a put option to buyout the royalty payments to third parties. The Company issued common stock valued at for six months ended December 31, 2007 of \$8,500 as compared to \$720,720. The Company had depreciation and amortization expenses for the six months ended December 31, 2007 of \$110,592 as compared to 2006 of \$763,450. The reduction in deprecation is directly related to the write off of the terminal asset capitalized in prior fiscal periods.

Cash provided by (used in) investing activities was \$300,581 for six months ended December 31, 2007, compared to (\$773,299) for 2006. Streamlining operations and capital budget curtailment practices promoted a reduction in equipment purchases for the Company. However, the Company continues to employ software development teams that are upgrading the existing proprietary software in our terminal and portal licensing agreement sold. The Company purchased equipment for six months ended December 31, 2007 of (\$28,123) as compared to (\$158,025) for December 31, 2006. The Company advanced proceeds to its affiliate company Card Activation Technologies, Inc. for the six months ended December 31, 2007 of (\$195,115) as compared to (\$182,157) for December 31, 2006.

Cash provided by financing activities was \$746,005 for the six months ended December 31, 2007 as compared to \$2,620,380 for 2006. Financing activities primarily consisted of proceeds from the increase in the financing of our licensing agreement through LeeCo. The Company does not have adequate cash flows to satisfy its obligations although have improved cash flow and anticipates have adequate cash flows in the upcoming fiscal periods. The Company received proceeds from the sale of common stock for six months ended December 31, 2007 of \$958,001 as compared to 2006 of \$3,452,324. The Company decrease the cost of raising capital was \$65,975 for the six months ended December 31, 2007 as compared to \$0 for 2006. The six months ended December 31, 2007 the chairman advanced funds of \$486,000 as compared to \$375,473 for 2006.

The Company has funding agreements with LeeCo Financial Service Inc. and Ladco Financial Group who provide exclusive funding for the License agreement between the Company and Licensing. The funding groups accept contracts and adopt the same terms and conditions that the Company and Licensing have agreed. In prior years Ladco required to personally guarantee the licensing agreements which were a financial burden to the Company. In fiscal 2006, the Company no longer sought funding through Ladco and has consistently sought the funding of LeeCo. LeeCo does not require personal guarantees of licensing agreements other than hospital agreements. LeeCo requires the Company to personally guarantee the hospital agreements due to the size and volume of transaction with the terminal and web portals.

Table of Contents

The Company expects increased cash flow from its existing services fees which include transaction processing, benefit claims processing, direct terminal sales, and credit card processing. The decrease in cost of deliverables is directly related to the sales through our telesales. Further we anticipate increase income from our TESIA-PC contracts that have a higher volume of credit card processing in which we receive a fee per month on all transactions with a 15 cent per transaction fee in fiscal 2008.

On September 14, 2006 the Company renegotiated the Ladco debt. The Company agreed to pay penalties and late fees of \$268,585.73 in exchange the renegotiated balance would only carry an interest rate of 3% reduced from 26% in the original note. The Company originally owed \$3,015,063 and renegotiated the balance to \$3,880,500 which included the accrued penalties and late fees. Further the Company would be able to pay the remaining balance of the note for 39 months at \$99,500 payments per month until paid in full. Under the renegotiated note the note matures on October 2009

LeeCo agreement adopts the agreement that the Company executes with the customer. LeeCo collects all funds through ACH and is paid from those proceeds. The excess of those proceeds are collected by the Company. LeeCo holds as collateral all the proceeds from the customer leases, access fees and all cash collections and is secured from all assets of the Company.

The licensing agreement is executed between the professional and the MedCom. During the course of the agreement the Company ACH's the accounts of the professionals and LeeCo collects the fees and reduces the liability for the licensing fees collected and returns any excess transaction fees to the Company. The professional does not finance their agreement with LeeCo, the Company finances the agreement. LeeCo is not a related party of the Company. The financing of the licensing agreement is calculated as part of our revenue recognition process as the monthly collection of the licensing fee is recorded against the outstanding balance. Revenue is not recognized in excess of the cash received from our financing of the likening agreement in accordance with SAB 101. The guarantees that are provided in connection with the hospital agreements have not changed our revenue recognition process except the accrual of the interest expense related to the unpaid balances.

The Company has a fixed and determinable licensing fee and gateway access fees. The Company has all customer agreements over a period of 24 -60 months. This period the Company updates software, and provides various transaction fees outlined as deliverables. The Company receives payments through out the term of the agreement. The Company incurs and recognizes expenses in the initial software installation that is outlined in the multiple deliverables and continues to service the customer with the remaining deliverables through out the terms of the contract. Revenue is recognized when the customer pays the ongoing payment through out the term of the contract. Revenue is recognized at the initial installation based upon the cost of deliverables at the time of installation.

The Company has a fixed and determinable licensing arrangement as the Company enforces all licensing agreements as they are noncancellable, the Company has never altered the terms of the agreement with the original licensing agreement, the Company has incremental risk in this arrangement. The Company recognizes revenue over the terms of the agreement and further recognizes revenue based upon the costs of deliverable that is required in the initial installation of the software and continues to provide deliverables in accordance with the terms of the agreement.

The Company has a standard practice to enter into a financing arrangement with LeeCo and does not provide a concession which makes it fixed and determinable licensing arrangement. MedCom has incremental risk in the financing arrangement with LeeCo and thus has fixed and determinable licensing arrangement.



## Table of Contents

The customer does not arrange any financing of the software. The Company has recourse in the financing arrangement. The Company recognizes revenue upon delivery of the software elements and over the term of the agreement based up on the deliverables delivered under the terms of the agreement.

The Company participates in the financing of the customers' term contract. The Company recognizes revenues to the extent of the expenses paid for the multiple elements of each deliverables and then recognizes revenue over the term of the contract. The Company defers any revenue of the contract and recognizes that deferred revenue over the remaining term of the contract.

### ITEM 3. CONTROLS AND PROCEDURES

#### Evaluation of Disclosure Controls and Procedures

##### a) Evaluation of Disclosure Controls and Procedures.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act"). Disclosure controls and procedures are the controls and other procedures that we designed to ensure that we record, process, summarize and report in a timely manner the information we must disclose in reports that we file with or submit to the Securities and Exchange Commission under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Principal Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

##### b) Changes in Internal Control over Financial Reporting

During the Quarter ended December 31, 2007, there was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

#### Other Considerations

There are numerous factors that affect our business and the results of its operations. Sources of these factors include general economic and business conditions, federal and state regulation of business activities, the level of demand for the Company's product or services, the level and intensity of competition in the medical transaction processing industry and the pricing pressures that may result, the Company's ability to develop new services based on new or evolving technology and the market's acceptance of those new services, the Company's ability to timely and effectively manage periodic product transitions, the services, customer and geographic sales mix of any particular period, and the ability to continue to improve infrastructure including personnel and systems, to keep pace with the growth in its overall business activities.



Table of Contents

Forward-Looking Statements

Except for historical information contained herein, this Form 10-QSB contains express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company may make written or oral forward-looking statements from time to time in filings with the SEC, in press releases, or otherwise. The words “believes,” “expects,” “anticipates,” “intends,” “forecasts,” “project,” “plans,” “estimates” and other expressions identify forward-looking statements. Such statements reflect the current views with respect to future events and financial performance or operations and are only as of the date the statements are made. Forward-looking statements involve risks and uncertainties and readers are cautioned not to place undue reliance on forward-looking statements. The Company’s actual results may differ materially from such statements. Factors that cause or contribute to such differences include, but are not limited to, those discussed elsewhere in this Form 10-QSB, as well as those discussed in Form 10-KSB which is incorporated by reference in this Form 10-QSB.

Management believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in such forward-looking statements will be realized. The inclusion of such forward-looking information should not be regarded, as a representation that the future events, plans, or expectations contemplated will be achieved. The Company undertakes no obligation to publicly update, review, or revise any forward-looking statements to reflect any change in expectations or any change in events, conditions, or circumstances on which any such statements are based. Our filings with the Securities Exchange Commission, including the Form 10-KSB, and may be accessed at the SEC’s web site, [www.sec.gov](http://www.sec.gov).

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

MedCom is involved in various legal proceedings and claims as described in our Form 10-KSB for the year ended June 30, 2007. No material developments occurred in any of these proceedings during the quarter ended December 31, 2007. The costs and results associated with these legal proceedings could be significant and could affect the results of future operations.

ITEM 2. CHANGES IN SECURITIES AND SMALL BUSINESS ISSUER PURCHASES OF EQUITY SECURITIES

There were no changes in securities and small business issuer purchase of equity securities during the period ended December 31, 2007, except the company issued 2,157,357 common shares for \$958,001 in a private placement. We have sold or issued the following securities not registered under the Securities Act by reason of the exemption afforded under Section 4(2) of the Securities Act of 1933, within the last quarter. Except as stated below, no underwriting discounts or commissions were paid with respect to any of the following transactions. The offer and sale of the following securities was exempt from the registration requirements of the Securities Act under Rule 506 insofar as (1) except as stated below, each of the investors was accredited within the meaning of Rule 501(a); (2) the transfer of the securities were restricted by the company in accordance with Rule 502(d); (3) there were no more than 35 non-accredited investors in any transaction within the meaning of Rule 506(b), after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months preceding the transaction; and (4) none of the offers and sales were effected through any general solicitation or general advertising within the meaning of Rule 502(c). Also, was a Form D filed and blue sky filings made (if a private placement)



Table of Contents

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

There were no defaults upon senior securities during the period ended December 31, 2007.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There were no matters submitted to the vote of securities holders during the period ended December 31, 2007.

ITEM 5. OTHER INFORMATION

None

Exhibits

- 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
- 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.
- 32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.
- 32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Registrant  
Date: February 14, 2008

MedCom USA Incorporated  
By: /s/ William P. Williams

William P. Williams  
Chairman, President Chief Executive Officer (Principle  
Executive Officer, Principle Financial Officer)